Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE1/PHASE2
INTERVENTIONAL
2024-06-01
2024-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG
NCT07216391
STOP-T1D Low-Dose (ATG)
NCT04291703
Low-dose IL-2 in Established T1D - The "PROREG" Study
NCT03243058
Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus
NCT07142252
New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical Trial
NCT00100178
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A
Participants in this group will receive Thymoglobulin, Aldesleukin, Adalimumab, and Exenatide over a period of 52 weeks.
* Anti-Thymocyte Globulin (ATG or Thymoglobulin®) will be administered at a dose of 2.5mg/kg (2 infusions, 0.5 and 2mg/kg) Days 1 and 2
* Adalimumab (Humira®) will be administered at a dose of 50 mg every month, for 1 year
* Low-dose Interleukin 2 (Aldesleukin; IL-2 or Proleukin®) will be administered 1 million IU/dose; 5 consecutive days (days 10-14), \& then every 2 weeks, for 52 weeks
* Exenatide (Bydureon®): 2 mg SC weekly up to 52 weeks.
Anti-Thymocyte Globulin (ATG)
2.5 mg/kg administered as two divided infusions of 0.5 mg/kg and 2 mg/kg on Days 1 and 2.
Interleukin 2
1 million IU per dose administered subcutaneously for 5 consecutive days on Days 10-14, and then every two weeks.
Exenatide
2 mg administered subcutaneously weekly for up to 52 weeks.
Adalimumab
50 mg administered subcutaneously once a month for 1 year.
Arm B
Participants in this group will receive the placebos for Thymoglobulin, Aldesleukin, Adalimumab, Exenatide, and Neulasta over a period of 52 weeks.
ATG Placebo
ATG placebo mimicking Thymoglobulin administered intravenously.
IL-2 Placebo
IL-2 placebo mimicking Aldesleukin administered subcutaneously.
Adalimumab Placebo
Placebo mimicking Adalimumab administered subcutaneously.
Exenatide Placebo
Placebo mimicking Exenatide administered subcutaneously.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anti-Thymocyte Globulin (ATG)
2.5 mg/kg administered as two divided infusions of 0.5 mg/kg and 2 mg/kg on Days 1 and 2.
Interleukin 2
1 million IU per dose administered subcutaneously for 5 consecutive days on Days 10-14, and then every two weeks.
Exenatide
2 mg administered subcutaneously weekly for up to 52 weeks.
Adalimumab
50 mg administered subcutaneously once a month for 1 year.
ATG Placebo
ATG placebo mimicking Thymoglobulin administered intravenously.
IL-2 Placebo
IL-2 placebo mimicking Aldesleukin administered subcutaneously.
Adalimumab Placebo
Placebo mimicking Adalimumab administered subcutaneously.
Exenatide Placebo
Placebo mimicking Exenatide administered subcutaneously.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Subject must be able to understand and provide informed consent.
2. Males and females, 18-35 years of age.
3. New onset T1D for no longer than 120 days at the time of randomization.
4. Affected by T1D, according to ADA standard criteria, and confirmed by positivity of at least one T1D-associated autoantibody, to GAD65, IA-2, ZnT8, or insulin autoantibodies (if patient has been treated with insulin for less than 2 weeks).
5. Being on insulin therapy.
6. Stimulated C-peptide peak level \>0.2 nmol/L at the baseline 1 visit MMTT.
7. Female subjects of childbearing potential must have a negative pregnancy test upon study entry.
8. Female (and male) subjects with reproductive potential must agree to use two FDA approved methods of birth control for the entire duration of the study.
9. Adequate venous access to support study required blood draws.
Exclusion Criteria
2. BMI\>30 Kg/m2.
3. Contra-indications to ATG, GCSF, exenatide, etanercept and IL-2 (as per package insert, e.g., knowledge of hypersensitivity to drugs or its excipients).
4. Uncompensated heart failure, fluid overload, myocardial infarction or liver disease or severe impairment of a vital organ within the last 6 weeks before enrollment.
5. Any of the following laboratory findings: hemoglobin \<10.0 g/dL; leukocytes \<3,000/μL; neutrophils \<1,500/μL; lymphocytes \<800/μL; platelets \<100,000/μL.
6. Any sign or diagnosis of significant chronic active infection (e.g., hepatitis, tuberculosis, EBV, or CMV), or screening laboratory evidence consistent with a significant chronic active infection (such as positive for HIV, IGRA test for TB, or hepatitis B-C).
7. Ongoing acute infections, e.g., acute respiratory tract urinary tract, or gastrointestinal tract infections.
8. Ongoing or anticipated use of diabetes medications other than insulin.
9. Current or ongoing use of non-insulin pharmaceuticals that affect glycemic control within prior 7 days of screening.
10. Current or prior use of immunomodulators or systemic steroids in the last 2 months that could potentially affect diabetes or immunologic status.
11. Recent recipient of any licensed or investigational live attenuated vaccine(s) within 6 weeks of randomization.
12. Use of investigational drugs within 3 months of participation.
13. Concomitant therapy with immunosuppressive drugs, immunomodulators, or cytotoxic agents, or previous therapy less than 3 months from randomization.
14. History or diagnosis of malignancy. Any history of gastroparesis or other severe gastrointestinal disease, pancreatitis, thyroid nodules or malignancy with the exception of a history of localized basal cell carcinoma.
15. Presence of an allograft.
16. AST, ALT or Alkaline Phosphatase \>2 times upper limit of normal or total bilirubin \>1.5 times upper limit of normal.
17. Current, diagnosed, mental illness or current, diagnosed or self-reported drug or alcohol abuse; or any situation that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements.
18. Pregnancy or ongoing breastfeeding for women; unwillingness or inability of both females and males of childbearing age to use a reliable and effective form of contraception, for the entire duration of the study.
19. Past or current medical problems, or findings from physical examination, or laboratory testing, that are not listed above which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained.
18 Years
35 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Diabetes Research Institute Foundation
OTHER
Camillo Ricordi and Jay Skyler
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Camillo Ricordi and Jay Skyler
Professors, University of Miami Miller School of Medicine and Director/Deputy Director, Diabetes Research Institute
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rodolfo Alejandro, M.D.
Role: PRINCIPAL_INVESTIGATOR
Diabetes Research Institute, University of Miami
References
Explore related publications, articles, or registry entries linked to this study.
Skyler JS. Prevention and reversal of type 1 diabetes--past challenges and future opportunities. Diabetes Care. 2015 Jun;38(6):997-1007. doi: 10.2337/dc15-0349.
Skyler JS, Ricordi C. Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man. Diabetes. 2011 Jan;60(1):1-8. doi: 10.2337/db10-1114. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20150856
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.